Deferasirox (DFRA) is a novel oral chelator agent for treatment of iron overload. Although well established in the treatment of β-thalassemia major (β-TM), it has not yet been fully investigated in patients with sickle cell disease. The aim of this report is to present the preliminary results of a pilot study assessing the effect of 4 years of DFRA treatment in six patients with sickle cell disease who are in need of recurrent transfusions. Our results show a significant reduction of ferritin levels and improvement of liver hemosiderosis, assessed by means of magnetic resonance imaging T2* (MRI T2*). None of the patients presented any serious adverse effects and the treatment was well tolerated. These results are in accordance with previous studies about the use of DFRA in sickle cell disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/03630269.2012.746696 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasmodium ovale: Exploring an Atypical Presentation.
Cureus
November 2024
Infectious Diseases, Harlem Hospital Center, New York, USA.
Malaria is an infection caused by five different Plasmodium species. The most common are is more rarely reported and mostly has a benign course. We present a case of a 40-year-old male with a six-day history of headaches, chills, and fever who was initially evaluated in our emergency room, from where he was discharged after a negative workup for malaria.
View Article and Find Full Text PDFBackground Sickle cell disease (SCD) is a hereditary disorder marked by abnormal hemoglobin (HbS), leading to chronic hemolytic anemia, vaso-occlusive crises (VOCs), and multi-organ complications. In India, the prevalence of SCD is highest among tribal populations in states like Madhya Pradesh, Maharashtra, Odisha, and Assam, with the disease burden exacerbated by limited healthcare access, especially in rural regions. This study provides a comprehensive analysis of the demographic profile, clinical features, and treatment patterns of SCD patients at a tertiary healthcare center in Upper Assam, where the prevalence of SCD is high among the tea tribe communities.
View Article and Find Full Text PDFMycoplasma pneumoniae-Triggered Guillain-Barré Syndrome in Children: Two Case Reports of Different ICU Presentations.
Cureus
November 2024
Pediatric Neurology, King Fahad Medical City, Riyadh, SAU.
Guillain-Barré syndrome (GBS) is an acute immune-mediated polyneuropathy with diverse clinical presentations. Mycoplasma pneumoniae has been increasingly recognized as a potential trigger, particularly in pediatric cases. This case report presents two atypical cases of M.
View Article and Find Full Text PDFAlterations of T Cell Subsets Associated with Sickle Cell Trait.
Blood Genom Discov
October 2024
Department of Pathology and Laboratory Medicine, University of Vermont Larner College of Medicine, Burlington, VT 05405, USA.
Sickle cell trait (SCT) has been associated with alterations in various immune-related laboratory parameters including lower circulating lymphocyte counts. To further characterize the impact of SCT on the immune system, we performed flow cytometry of monocyte and lymphocyte immune cell subsets from peripheral blood mononuclear cells collected in a large, community-based cohort of SCT-positive (n = 68) and SCT-negative (n = 959) Black adults. SCT was significantly associated with lower proportions of CD8 and CD4 T cell subsets that include senescent-like markers of repeated immune system challenges.
View Article and Find Full Text PDFMalaria prophylaxis in sickle cell anaemia: some answers, more questions.
Lancet Infect Dis
December 2024
Cincinnati Children's Hospital, Cincinnati, OH, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!